The Individual Therapy for Patients With Wilson’s Disease

checkorphan
Learn more about:
Wilson disease
Related Clinical Trial
Clinical Study of UX701 AAV-Mediated Gene Transfer for the Treatment of Wilson Disease Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840 A Phase I/II Study of VTX-801 in Adult Patients With Wilson’s Disease Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects With Wilson Disease Copper Concentration and Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840 Study of Retinal Vascular Parameters in Patients With Wilson’s Disease Evaluation of Patients With Liver Disease ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders The Assessment of Copper Parameters in Wilson Disease Subjects on Standard of Care Treatment Establishment of Human Cellular Disease Models for Wilson Disease Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson’s Disease in Japan. Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine A Controlled Study of Potential Therapeutic Effect of Oral Zinc in Manifesting Carriers of Wilson Disease Plasma Exchange and Continuous Hemodiafiltration in Treatment of Wilson’s Disease-related Liver Failure The Individual Therapy for Patients With Wilson’s Disease Study of Zinc for Wilson Disease Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson’s Disease Study of Tetrathiomolybdate in Patients With Wilson Disease Efficacy and Safety of ALXN1840 (Formerly Named WTX101) Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease With an Extension Period of up to 60 Months WILSTIM – DBS (WILson STIMulation – Deep Brain Stimulation) Efficacy and Safety Study of Zinc Acetate to Treat Wilson’s Disease in Japan. Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis Inhibitory rTMS in Dystonic Wilson Patients Natural History of Wilson Disease A Registered Cohort Study on Wilson’s Disease sCD163 and sMR in Wilsons Disease – Associations With Disease Severity and Fibrosis Cohort Research on Wilson’s Disease Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson’s Disease Patients Efficacy and Safety Study of WTX101 in Adult Wilson Disease Patients

Brief Title

The Individual Therapy for Patients With Wilson's Disease

Official Title

The Individual Therapy for Patients With Wilson's Disease

Brief Summary

      Based on the genotype characteristics and genotype-phenotype-treatment prognosis data of
      Chinese WD patients, this study intends to further optimize the treatment regimen of Chinese
      WD patients and formulate individualized treatment regimens for each genotype, so as to
      further improve the prognosis of patients.

Detailed Description

      The purpose of the study is to evaluate treatment regimen efficacy based on different
      mutations, and Zinc treatment in presymptomatic WD patients.

Study Phase

Early Phase 1

Study Type

Interventional

Primary Outcome

Serum ceruloplasmin

Condition

Wilson's Disease

Intervention

DMPS

Study Arms / Comparison Groups

 homo-R778L
Description:  When patients carrying homo-R778L mutation are in hospital, they receive DMPS treatment. Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Drug

Estimated Enrollment

400

Start Date

March 15, 2019

Completion Date

December 31, 2024

Primary Completion Date

December 31, 2024

Eligibility Criteria

        Inclusion Criteria:

          -  Genetic diagnosis of Wilson's disease

          -  Presymptomatic patients with Wilson's disease

        Exclusion Criteria:

          -  Movement disorder due to other definite causes instead of Wilson's disease

          -  Severe Lung, kidney or liver disease

          -  Neoplastic Disease

Gender

All

Ages

N/A - N/A

Accepts Healthy Volunteers

No

Contacts

Zhi-Ying Wu, MD&PhD, +86-571-87783569, [email protected]

Location Countries

China

Location Countries

China

Administrative Informations

NCT ID

NCT03957720

Organization ID

WuZYLab-WD

Responsible Party

Sponsor

Study Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Study Sponsor

Zhi-Ying Wu, MD&PhD, Principal Investigator, Zhejiang University

Verification Date

May 2019